SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. – ZNTL

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zentalis Pharmaceuticals, Inc. – ZNTL

NEW YORK, July 10, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Zentalis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On June 18, 2024, Zentalis announced that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).” 

On this news, Zentalis’s stock price fell $4.25 per share, or 50.66%, to close at $4.14 per share on June 18, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-zentalis-pharmaceuticals-inc—zntl-302193927.html

SOURCE Pomerantz LLP